NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Nov 2, 2022--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment conferences in November.
Event: |
| Stifel 2022 Healthcare Conference |
Date: |
| Tuesday, November 15, 2022 |
Time: |
| 8:35-9:05 am ET |
Event: |
| 5th Annual Evercore ISI HealthCONx Conference |
Date: |
| Wednesday, November 30, 2022 |
Time: |
| 11:45-12:05 pm ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau ® is a registered trademark of Evolus, Inc.
Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221102005385/en/
CONTACT: Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email:david.erickson@evolus.com
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH CONSUMER WOMEN OTHER HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Evolus
Copyright Business Wire 2022.
PUB: 11/02/2022 08:45 AM/DISC: 11/02/2022 08:47 AM
http://www.businesswire.com/news/home/20221102005385/en